The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Open accessAbstract
The tumor-killing properties of T cells provide tremendous opportunities to treat cancer. Adoptive T cell therapies have begun to harness this potential by endowing a functionally diverse repertoire of T cells with genetically modified, tumor-specific recognition receptors. Normally, this antigen recognition function is mediated by an αβ T cell receptor (TCR), but the dominant therapeutic forms currently in development are synthetic constructs called chimeric antigen receptors (CARs). While CAR-based adoptive cell therapies are already showing great promise, their basic mechanistic properties have been studied in less detail compared with those of αβ TCRs. In this review, we compare and contrast various features of TCRs versus CARs, with a goal of highlighting issues that need to be addressed to fully exploit the therapeutic potential of both.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Mueller, D. L., Jenkins, M. K., & Schwartz, R. H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.002305 · Cited by 1,493
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
HOW TCRS BIND MHCS, PEPTIDES, AND CORECEPTORS
Rudolph, M. G., Stanfield, R. L., & Wilson, I. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115658 · Cited by 1,310
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,179
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,148
Serial triggering of many T-cell receptors by a few peptide–MHC complexes
Valitutti, S., Müller, S., Cella, M., Padovan, E., & Lanzavecchia, A. (1995) · Nature · doi:10.1038/375148a0 · Cited by 1,128
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
The role of TNF superfamily members in T-cell function and diseases
Croft, M. (2009) · Nature Reviews Immunology · doi:10.1038/nri2526 · Cited by 920
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
Direct observation of ligand recognition by T cells
Irvine, D. J., Purbhoo, M. A., Krogsgaard, M., & Davis, M. M. (2002) · Nature · doi:10.1038/nature01076 · Cited by 820
Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 735
Till, B. G., Jensen, M. C., Wang, J., Chen, E. Y., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 722
Lamers, C. H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, C., Vulto, A., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 704
Evidence that a Single Peptide–MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response
Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J., & Eisen, H. N. (1996) · Immunity · doi:10.1016/s1074-7613(00)80483-5 · Cited by 703
Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603
T cell killing does not require the formation of a stable mature immunological synapse
Purbhoo, M. A., Irvine, D. J., Huppa, J. B., & Davis, M. M. (2004) · Nature Immunology · doi:10.1038/ni1058 · Cited by 577
Adusumilli, P. S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 572
Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0159 · Cited by 565
The kinetic-segregation model: TCR triggering and beyond
Davis, S. J., & van der Merwe, P. A. (2006) · Nature Immunology · doi:10.1038/ni1369 · Cited by 561
Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
Hudecek, M., Sommermeyer, D., Kosasih, P. L., Silva-Benedict, A., Liu, L., Rader, C., Jensen, M. C., & Riddell, S. R. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0127 · Cited by 532
Pulè, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 487
Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487
Mechanisms for T cell receptor triggering
van der Merwe, P. A., & Dushek, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri2887 · Cited by 482
Gil, D., Schamel, W. W. A., Montoya, M., Sánchez-Madrid, F., & Alarcón, B. (2002) · Cell · doi:10.1016/s0092-8674(02)00799-7 · Cited by 461
Xu, C., Gagnon, E., Call, M. E., Schnell, J. R., Schwieters, C. D., Carman, C. V., Chou, J. J., & Wucherpfennig, K. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.044 · Cited by 456
Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A. K., Dentchev, T., Thekkat, P., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 454
Directed evolution of human T-cell receptors with picomolar affinities by phage display
Li, Y., Moysey, R., Molloy, P. E., Vuidepot, A.-L., Mahon, T., Baston, E., Dunn, S., Liddy, N., Jacob, J., Jakobsen, B. K., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1070 · Cited by 442
The αβ T Cell Receptor Is an Anisotropic Mechanosensor
Kim, S. T., Takeuchi, K., Sun, Z.-Y. J., Touma, M., Castro, C. E., Fahmy, A., Lang, M. J., Wagner, G., & Reinherz, E. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.052712 · Cited by 410
Adoptive cellular therapy: A race to the finish line
June, C. H., Riddell, S. R., & Schumacher, T. N. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3643 · Cited by 403
Caruso, H. G., Hurton, L. V., Najjar, A., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K., Singh, H., Huls, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0139 · Cited by 397
Huang, J., Brameshuber, M., Zeng, X., Xie, J., Li, Q.-J., Chien, Y.-H., Valitutti, S., & Davis, M. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.036 · Cited by 385
Agonist/endogenous peptide–MHC heterodimers drive T cell activation and sensitivity
Krogsgaard, M., Li, Q.-J., Sumen, C., Huppa, J. B., Huse, M., & Davis, M. M. (2005) · Nature · doi:10.1038/nature03391 · Cited by 346
Fidelity of T Cell Activation Through Multistep T Cell Receptor ζ Phosphorylation
Kersh, E. N., Shaw, A. S., & Allen, P. M. (1998) · Science · doi:10.1126/science.281.5376.572 · Cited by 341
Biophysical mechanism of T-cell receptor triggering in a reconstituted system
James, J. R., & Vale, R. D. (2012) · Nature · doi:10.1038/nature11220 · Cited by 323
Frigault, M. J., Lee, J., Basil, M. C., Carpenito, C., Motohashi, S., Scholler, J., Kawalekar, O. U., Guedan, S., McGettigan, S. E., Posey, A. D., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0186 · Cited by 323
Guest, R. D., Hawkins, R. E., Kirillova, N., Cheadle, E. J., Arnold, J., O'Neill, A., Irlam, J., Chester, K. A., Kemshead, J. T., Shaw, D. M., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000161397.96582.59 · Cited by 318
Chapuis, A. G., Ragnarsson, G. B., Nguyen, H. N., Chaney, C. N., Pufnock, J. S., Schmitt, T. M., Duerkopp, N., Roberts, I. M., Pogosov, G. L., Ho, W. Y., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004916 · Cited by 311
Hombach, A., Wieczarkowiecz, A., Marquardt, T., Heuser, C., Usai, L., Pohl, C., Seliger, B., & Abken, H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6123 · Cited by 299
In vitro evolution of a T cell receptor with high affinity for peptide/MHC
Holler, P. D., Holman, P. O., Shusta, E. V., O'Herrin, S., Wittrup, K. D., & Kranz, D. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.080078297 · Cited by 295
Self-citationSong, D.-G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.-P., Ji, C., Figini, M., June, C. H., Coukos, G., & Powell, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0422 · Cited by 287
Watanabe, K., Terakura, S., Martens, A. C., van Meerten, T., Uchiyama, S., Imai, M., Sakemura, R., Goto, T., Hanajiri, R., Imahashi, N., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402346 · Cited by 284
An Enigmatic Tail of CD28 Signaling
Boomer, J. S., & Green, J. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002436 · Cited by 283
A Zinc Clasp Structure Tethers Lck to T Cell Coreceptors CD4 and CD8
Kim, P. W., Sun, Z.-Y. J., Blacklow, S. C., Wagner, G., & Eck, M. J. (2003) · Science · doi:10.1126/science.1085643 · Cited by 276
Bridgeman, J. S., Hawkins, R. E., Bagley, S., Blaylock, M., Holland, M., & Gilham, D. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901766 · Cited by 267
Chmielewski, M., Hombach, A., Heuser, C., Adams, G. P., & Abken, H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7647 · Cited by 260
Aleksic, M., Liddy, N., Molloy, P. E., Pumphrey, N., Vuidepot, A., Chang, K., & Jakobsen, B. K. (2012) · European Journal of Immunology · doi:10.1002/eji.201242606 · Cited by 248
Li, Q.-J., Dinner, A. R., Qi, S., Irvine, D. J., Huppa, J. B., Davis, M. M., & Chakraborty, A. K. (2004) · Nature Immunology · doi:10.1038/ni1095 · Cited by 232
Hombach, A., Hombach, A. A., & Abken, H. (2010) · Gene Therapy · doi:10.1038/gt.2010.91 · Cited by 228
Li, Y.-C., Chen, B.-M., Wu, P.-C., Cheng, T.-L., Kao, L.-S., Tao, M.-H., Lieber, A., & Roffler, S. R. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0900775 · Cited by 220
TCRs with high affinity for foreign pMHC show self-reactivity
Holler, P. D., Chlewicki, L. K., & Kranz, D. M. (2003) · Nature Immunology · doi:10.1038/ni863 · Cited by 217
Self-citationCD4 and CD8 binding to MHC molecules primarily acts to enhance Lck delivery
Artyomov, M. N., Lis, M., Devadas, S., Davis, M. M., & Chakraborty, A. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010568107 · Cited by 207
Designing chimeric antigen receptors to effectively and safely target tumors
Jensen, M. C., & Riddell, S. R. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.002 · Cited by 204
T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing
Kudo, K., Imai, C., Lorenzini, P., Kamiya, T., Kono, K., Davidoff, A. M., Chng, W. J., & Campana, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1365 · Cited by 191
CAR T Cells for Solid Tumors: Armed and Ready to Go?
Kakarla, S., & Gottschalk, S. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000032 · Cited by 190
Kjer-Nielsen, L., Dunstone, M. A., Kostenko, L., Ely, L. K., Beddoe, T., Mifsud, N. A., Purcell, A. W., Brooks, A. G., McCluskey, J., & Rossjohn, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402295101 · Cited by 181
Ehrlich, L. I. R., Ebert, P. J. R., Krummel, M. F., Weiss, A., & Davis, M. M. (2002) · Immunity · doi:10.1016/s1074-7613(02)00481-8 · Cited by 172
Tammana, S., Huang, X., Wong, M., Milone, M. C., Ma, L., Levine, B. L., June, C. H., Wagner, J. E., Blazar, B. R., & Zhou, X. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.122 · Cited by 165
The interplay of effector and regulatory T cells in cancer
Roychoudhuri, R., Eil, R. L., & Restifo, N. P. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.003 · Cited by 154
Zhang, T., Wu, M.-R., & Sentman, C. L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103495 · Cited by 141
Molecular architecture of the αβ T cell receptor–CD3 complex
Birnbaum, M. E., Berry, R., Hsiao, Y., Chen, Z., Shingú-Vázquez, M., Yu, X., Waghray, D., Fischer, S., McCluskey, J., Rossjohn, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420936111 · Cited by 126
Yachi, P. P., Ampudia, J., Gascoigne, N. R. J., & Żal, T. (2005) · Nature Immunology · doi:10.1038/ni1220 · Cited by 125
Beddoe, T., Chen, Z., Clements, C. S., Ely, L. K., Bushell, S. R., Vivian, J. P., Kjer‐Nielsen, L., Pang, S. S., Dunstone, M. A., Liu, Y. C., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.018 · Cited by 124
Stone, J. D., Harris, D. T., & Kranz, D. M. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.003 · Cited by 122
Self-citationDynamics of Cell Surface Molecules During T Cell Recognition
Davis, M. M., Krogsgaard, M., Huppa, J. B., Sumen, C., Purbhoo, M. A., Irvine, D. J., Wu, L. C., & Ehrlich, L. I. R. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161625 · Cited by 118
Stone, J. D., Aggen, D. H., Schietinger, A., Schreiber, H. W., & Kranz, D. M. (2012) · OncoImmunology · doi:10.4161/onci.20592 · Cited by 102
Self-citationAnikeeva, N., Lebedeva, T., Clapp, A. R., Goldman, E. R., Dustin, M. L., Mattoussi, H. M., & Sykulev, Y. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607771103 · Cited by 100
Targeting cancer-specific mutations by T cell receptor gene therapy
Blankenstein, T. J. F., Leisegang, M., Uckert, W., & Schreiber, H. W. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.005 · Cited by 89
Ligand-engaged TCR is triggered by Lck not associated with CD8 coreceptor
Casas, J., Brzostek, J., Zarnitsyna, V. I., Hong, J., Wei, Q., Hoerter, J. A. H., Fu, G., Ampudia, J., Zamoyska, R., Zhu, C., et al. (2014) · Nature Communications · doi:10.1038/ncomms6624 · Cited by 86
Re‐adapting T cells for cancer therapy: from mouse models to clinical trials
Stromnes, I. M., Schmitt, T. M., Chapuis, A. G., Hingorani, S. R., & Greenberg, P. D. (2013) · Immunological Reviews · doi:10.1111/imr.12141 · Cited by 82
The Impact of TCR-Binding Properties and Antigen Presentation Format on T Cell Responsiveness
Chervin, A. S., Stone, J. D., Holler, P. D., Bai, A., Chen, J., Eisen, H. N., & Kranz, D. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900054 · Cited by 75
Self-citationChimeric Antigen Receptor T Cells for Cancer Immunotherapy
Curran, K. J., & Brentjens, R. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.3449 · Cited by 60
The role of T cell receptor signaling thresholds in guiding T cell fate decisions
Zikherman, J., & Au‐Yeung, B. B. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.012 · Cited by 53
CD19 CAR Therapy for Acute Lymphoblastic Leukemia
Sadelain, M., Brentjens, R. J., Rivière, I., & Park, J. H. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e360 · Cited by 51
Improving the efficacy and safety of engineered T cell therapy for cancer
Shi, H., Liu, L., & Wang, Z. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.09.015 · Cited by 48
Engels, B., Chervin, A. S., Sant, A. J., Kranz, D. M., & Schreiber, H. W. (2012) · Molecular Therapy · doi:10.1038/mt.2011.286 · Cited by 48
Self-citationStone, J. D., Harris, D. T., Soto, C. M., Chervin, A. S., Aggen, D. H., Roy, E. J., & Kranz, D. M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1586-z · Cited by 39
Self-citationNovel Approaches to Enhance the Specificity and Safety of Engineered T Cells
Fedorov, V. D., Sadelain, M., & Kloss, C. C. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000040 · Cited by 35
Evidence Implicating the Ras Pathway in Multiple CD28 Costimulatory Functions in CD4+ T Cells
Janardhan, S. V., Praveen, K., Marks, R., & Gajewski, T. F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024931 · Cited by 32
Brentjens, R. J. (2013) · Cited by 29
Cited by
Navigating CAR-T cells through the solid-tumour microenvironment
Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 551
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061283 · Cited by 531
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., Zhao, Y., & June, C. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.002 · Cited by 506
Current Progress in CAR-T Cell Therapy for Solid Tumors
Ma, S., Li, X., Wang, X., Cheng, L., Li, Z., Zhang, C., Ye, Z., & Qian, Q. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.34213 · Cited by 496
New development in CAR-T cell therapy
Wang, Z., Wu, Z., Liu, Y., & Han, W. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0423-1 · Cited by 396
Metadata
- Authors
- Harris, D. T., & Kranz, D. M.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 37
- Issue
- 3
- Pages
- 220-230
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2217081146
- Cited by
- 257
- References
- 98
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.